a 71% year-over-year increase. We've driven increased adoption by pulmonologists supported by TEPEZA's unique profile to treat patients with multiple severe uncontrolled asthma triggers and drivers. TEZSPIRE has strong future growth potential, given the need to treat the 2.5 million...
In my view, the company’s third-quarter results made it clear that its operating fundamentals are healthy. Amgen’s deleveraging efforts are also coming along. The dividend is well-covered, with room to keep growing. Finally, the stock looks to be a solid value at the current share price....
Putting the results in a broader context, our double-digit increase in revenues was driven by the continued volume driven growth of many of our innovative products, the strong uptake of our high-quality biosimilars and the relative stability of our base business, which is proving resilient in th...
Dividend Share 9.13 Earnings Share 10.97 Revenue Per Share 63.49 Quarterly Revenue Growth 0.094 The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of ...
Repatha and Prolia alone in 2024, ongoing and future investments will support MariTide and other products across the portfolio. In addition, we returned capital to shareholders as we paid competitive dividend of $2.25 per share in the second quarter. This represented a 6% increase compared to ...